FI3554474T3 - Mikafungiinikoostumuksia - Google Patents

Mikafungiinikoostumuksia Download PDF

Info

Publication number
FI3554474T3
FI3554474T3 FIEP17829412.0T FI17829412T FI3554474T3 FI 3554474 T3 FI3554474 T3 FI 3554474T3 FI 17829412 T FI17829412 T FI 17829412T FI 3554474 T3 FI3554474 T3 FI 3554474T3
Authority
FI
Finland
Prior art keywords
packaged
sealed container
pharmaceutical composition
aqueous pharmaceutical
micafungin
Prior art date
Application number
FIEP17829412.0T
Other languages
English (en)
Finnish (fi)
Inventor
Sydney J Cope
Christine L Rebbeck
Mark J Doty
Original Assignee
Baxter Int
Baxter Healthcare Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baxter Int, Baxter Healthcare Sa filed Critical Baxter Int
Application granted granted Critical
Publication of FI3554474T3 publication Critical patent/FI3554474T3/fi

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
FIEP17829412.0T 2016-12-16 2017-12-15 Mikafungiinikoostumuksia FI3554474T3 (fi)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662435695P 2016-12-16 2016-12-16
PCT/US2017/066652 WO2018112330A1 (en) 2016-12-16 2017-12-15 Micafungin compositions

Publications (1)

Publication Number Publication Date
FI3554474T3 true FI3554474T3 (fi) 2024-02-21

Family

ID=60972375

Family Applications (1)

Application Number Title Priority Date Filing Date
FIEP17829412.0T FI3554474T3 (fi) 2016-12-16 2017-12-15 Mikafungiinikoostumuksia

Country Status (11)

Country Link
US (2) US12403173B2 (enExample)
EP (1) EP3554474B1 (enExample)
JP (2) JP2020510619A (enExample)
AU (1) AU2017376960B2 (enExample)
DK (1) DK3554474T3 (enExample)
ES (1) ES2972008T3 (enExample)
FI (1) FI3554474T3 (enExample)
HU (1) HUE066069T2 (enExample)
PL (1) PL3554474T3 (enExample)
PT (1) PT3554474T (enExample)
WO (1) WO2018112330A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111044636A (zh) * 2019-12-30 2020-04-21 卓和药业集团有限公司 米卡芬净含量的分析方法
US20220040092A1 (en) * 2020-06-27 2022-02-10 RK Pharma Solutions LLC Ready to use injectable formulations of Micafungin Sodium
CN112710753A (zh) * 2020-12-18 2021-04-27 卓和药业集团有限公司 米卡芬净有关物质的分析方法
WO2024233925A1 (en) * 2023-05-11 2024-11-14 Hikma Pharmaceuticals Usa Inc. Stable micafungin compositions

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5849843A (en) 1993-11-16 1998-12-15 Baxter International Inc. Polymeric compositions for medical packaging and devices
US5998019A (en) 1993-11-16 1999-12-07 Baxter International Inc. Multi-layered polymer structure for medical products
MX9702531A (es) 1994-10-07 1997-06-28 Fujisawa Pharmaceutical Co Compuesto nuevo.
TWI233805B (en) 1999-07-01 2005-06-11 Fujisawa Pharmaceutical Co Stabilized pharmaceutical composition in lyophilized form as antifungal agent
EP1193261A1 (en) 2000-10-02 2002-04-03 Warner-Lambert Company New thiadiazoles and their use as phosphodiesterase-7 inhibitors
US6991800B2 (en) * 2002-06-13 2006-01-31 Vicuron Pharmaceuticals Inc. Antifungal parenteral products
CN103360486A (zh) 2004-08-18 2013-10-23 诺瓦生命科学有限公司 包含含有精氨酸和/或赖氨酸的基序的抗微生物肽
WO2008137128A2 (en) 2007-05-03 2008-11-13 Northeastern University Methods of treating fungal infections
AU2013254940A1 (en) 2008-04-21 2014-01-16 Otonomy, Inc. Auris formulations for treating otic diseases and conditions
MX2010012451A (es) 2008-05-15 2010-12-07 Baxter Int Formulaciones farmaceuticas estables.
GB0817121D0 (en) 2008-09-18 2008-10-29 Univ St Andrews Anti-fungal therapy
WO2010110686A1 (en) 2009-03-27 2010-09-30 Pathway Therapeutics Limited Pyrimidinyl and 1,3,5 triazinyl benzimidazoles and their use in cancer therapy
US20110071072A1 (en) * 2009-08-28 2011-03-24 Georgetown University, A Congressionally Chartered Institution Of Higher Education Antifungal Bone Cements
CN102614492B (zh) * 2011-01-31 2013-12-11 上海天伟生物制药有限公司 一种含有棘白菌素类抗真菌剂米卡芬净的液体药用组合物
CN102775476B (zh) * 2011-05-12 2015-01-07 上海天伟生物制药有限公司 一种米卡芬净钠盐的制备方法
CN102512379B (zh) * 2011-12-16 2017-03-08 深圳市健元医药科技有限公司 一种新型棘白菌素类抗真菌药物组合物及其制备方法
SI3677252T1 (sl) 2012-03-19 2024-02-29 Cidara Therapeutics, Inc. Sheme odmerjanja za spojine iz razreda ehinokandinov
DK3240529T3 (da) * 2014-12-31 2022-02-28 Galenicum Health S L U Stabile farmaceutiske sammensætninger omfattende micafungin
CN108290845B (zh) * 2015-10-07 2021-08-03 大日本住友制药株式会社 嘧啶化合物
IN2015MU03858A (enExample) * 2015-10-10 2015-10-23 Gufic Biosciences Ltd

Also Published As

Publication number Publication date
JP2020510619A (ja) 2020-04-09
US20250345386A1 (en) 2025-11-13
US20180169180A1 (en) 2018-06-21
HUE066069T2 (hu) 2024-07-28
EP3554474B1 (en) 2023-12-06
AU2017376960B2 (en) 2023-12-14
DK3554474T3 (da) 2024-02-19
PL3554474T3 (pl) 2024-04-15
WO2018112330A1 (en) 2018-06-21
AU2017376960A1 (en) 2019-05-23
PT3554474T (pt) 2024-02-12
JP2024012211A (ja) 2024-01-25
ES2972008T3 (es) 2024-06-10
EP3554474A1 (en) 2019-10-23
US12403173B2 (en) 2025-09-02

Similar Documents

Publication Publication Date Title
AR124140A2 (es) Formulaciones de anticuerpos
EA201492021A1 (ru) Антительный состав
FI3554474T3 (fi) Mikafungiinikoostumuksia
PH12017500844B1 (en) Stable protein solution formulation containing high concentration of an anti-vegf antibody
CL2013000815A1 (es) Composicion farmaceutica liquida de adm inistracion parenteral que comprende dexmedetomidina o una sal de la misma en una concentracion de 0,005 a 50 µg/ml y adicionalmente comprende cloruro de sodio en una concentracion de 0,01 a 2 % en peso, dispuesta dentro de un contenedor de vidrio sellado.
MY166045A (en) Abeta antibody formulation
AR067011A1 (es) Formulaciones de anticuerpos
JP2012515221A5 (enExample)
JP2017531682A5 (enExample)
MY197773A (en) Highly concentrated pharmaceutical formulations comprising anti-cd20 antibody
MX2010003923A (es) Formulacion farmaceutica de valsartan.
MX373040B (es) Composicion farmaceutica acuosa liquida que contiene derivados de ciclodextrina eterificada con conservador.
PE20142314A1 (es) Composiciones intranasales de dexmedetomidina y metodos de uso de ellas
JP2015134763A5 (enExample)
MX2011005633A (es) Formas de dosificacion solida de bendamustina.
HRP20201242T1 (hr) Tekući farmaceutski pripravak
JP2015535237A5 (enExample)
CY1112917T1 (el) Υγρες στοματικες συνθεσεις
HRP20200196T1 (hr) Fiziološki balansirane injektabilne formulacije fosnetupitanta
JP2019521102A5 (enExample)
FI3445331T3 (fi) Säilöntäainevapaita farmaseuttisia oftalmisia koostumuksia
MX2014009660A (es) Formulacion de anticuerpo anti-selectina p.
JP2020510619A5 (enExample)
AR098386A1 (es) Formulación para gonadotropinas
MX2017015202A (es) Formulaciones liquidas de celecoxib para administracion oral.